Gene-Activated Octacalcium Phosphate (OCP/VEGF) Versus Autologous Bone Graft for Single-Level TLIF in Degenerative Lumbar Stenosis
Surgeries · 22.02.2026 · 7 (1) · 29
DOI: 10.3390/surgeries7010029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgeries, online erschienen am 22.02.2026. Verfasst von Renat Madekhatovich Nurmukhametov und 9 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Autologous bone graft is widely used for lumbar interbody fusion but may increase operative time and donor-site morbidity. Gene-activated grafts combining an osteoconductive scaffold with pro-angiogenic signaling may provide comparable fusion without graft harvesting. The aim of this paper is to compare radiographic fusion and health-related quality of life after single-level transforaminal lumbar interbody fusion (TLIF) using a gene-activated octacalcium phosphate graft containing plasmid DNA encoding vascular endothelial growth factor (OCP/VEGF) versus an autologous bone graft.
Methods
200 adults undergoing first-time single-level TLIF for degenerative lumbar stenosis were allocated 1:1 to OCP/VEGF (n = 100) or autograft (n = 100), prospectively. CT-based fusion assessment and SF-36 outcomes were evaluated at 6 and 12 months follow-up.
Results
At 12 months after surgery, mean fusion-zone density was 617.6 ± 180.9 HU in the OCP/VEGF group versus 599.8 ± 181.9 HU in the autograft group (mean difference 17.8 HU; p = 0.484). Complete fusion on qualitative CT grading occurred in 77% versus 73%, respectively (risk difference 4%; p = 0.583). SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) improved significantly from baseline in both groups (p < 0.001), without clinically meaningful between-group differences at follow-up. Revision surgery occurred in 3% versus 5%.
Conclusions
In single-level TLIF for degenerative lumbar stenosis, OCP/VEGF produced radiographic fusion and patient-reported outcomes comparable to autograft at 12 months, supporting its use as an autograft-sparing alternative.
Zitieren
APA
Nurmukhametov, R. M., Abakirov, M. D., Kudryakov, S. A., Dosanov, M. K., Nuriddinov, D., Zhanchivdorj, B. B., Cevallos, K. S. B., Bozo, I. Y., Mateo, A. L. M., & Montemurro, N. (2026). Gene-Activated Octacalcium Phosphate (OCP/VEGF) Versus Autologous Bone Graft for Single-Level TLIF in Degenerative Lumbar Stenosis. Surgeries, 7(1), 29. https://doi.org/10.3390/surgeries7010029
Vancouver
Nurmukhametov RM, Abakirov MD, Kudryakov SA, Dosanov MK, Nuriddinov D, Zhanchivdorj BB, et al. Gene-Activated Octacalcium Phosphate (OCP/VEGF) Versus Autologous Bone Graft for Single-Level TLIF in Degenerative Lumbar Stenosis. Surgeries. 2026;7(1):29. doi:10.3390/surgeries7010029
BibTeX
@article{Nurmukhametov2026,
author = {Nurmukhametov, Renat Madekhatovich and Abakirov, Medetbek Dzhumabekovich and Kudryakov, Stepan Anatolyevich and Dosanov, Medet Kaskirbayevich and Nuriddinov, Dilerbek and Zhanchivdorj, Batzayaa Beis and Cevallos, Kerly Sulay Borja and Bozo, Ilya Yadigerovich and Mateo, Alberto Luis Martinez and Montemurro, Nicola},
title = {Gene-Activated Octacalcium Phosphate (OCP/VEGF) Versus Autologous Bone Graft for Single-Level TLIF in Degenerative Lumbar Stenosis},
journal = {Surgeries},
year = {2026},
volume = {7},
number = {1},
pages = {29},
doi = {10.3390/surgeries7010029}
}
EUVIMED